Loss of SLCO1B3 Drives Taxane Resistance in Prostate Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2016.251
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Adaptive Phenotype Drives Resistance to Androgen Deprivation Therapy in Prostate Cancer

Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2017English

Loss of FAT1 Drives Resistance to CDK4/6 Inhibitors in Breast Cancer

Cancer Discovery
Oncology
2018English

Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

Cancer Research
Cancer ResearchOncology
2014English

Loss of miR-516a-3p Mediates Upregulation of ABCC5 in Prostate Cancer and Drives Its Progression

OncoTargets and Therapy
OncologyPharmacology
2018English

Aneuploidy Drives Lethal Progression in Prostate Cancer

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2019English

A Memory of RPS25 Loss Drives Resistance Phenotypes

2019English

A Self-Fulfilling Prophecy: Comparing 177Lu-Psma Radioligand Therapy in Taxane Naïve vs Post-Taxane Metastasized Prostate Cancer Patients?

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

Multidrug Resistance in Prostate Cancer

Oncology Research and Treatment
Cancer ResearchOncologyHematology
2003English

Cancer Stem Cell Plasticity Drives Therapeutic Resistance

Cancers
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy